Lv1
10 积分 2024-08-20 加入
Phase I study on neoadjuvant combination immunotherapy with mogamulizumab and nivolumab for solid tumors
1个月前
已完结
Cancer incidence and mortality in China, 2022
1个月前
已完结
Unveiling the molecular and immunological drivers of antibody–drug conjugates in cancer treatment
2个月前
已完结
Navigating the landscape of EGFR TKI resistance in EGFR-mutant NSCLC — mechanisms and evolving treatment approaches
4个月前
已完结
[Expert consensus on diagnosis and treatment of lung cancer complicated with interstitial lung disease]
5个月前
已完结
Real-world evaluation of first-line treatment of extensive-stage small-cell lung cancer with atezolizumab plus platinum/etoposide: a focus on patients with brain metastasis
5个月前
已完结
Trastuzumab Deruxtecan in Patients With HER2-Overexpressing NSCLC: Results From Part 1 of the Open-Label, Multicenter, Phase 1b DESTINY-Lung03 Trial
5个月前
已完结
Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01): primary results of the HER2-overexpressing cohorts from a single-arm, phase 2 trial
5个月前
已完结
Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01): primary results of the HER2-overexpressing cohorts from a single-arm, phase 2 trial
6个月前
已完结
Effect of JAK/STAT signaling on anti-PD-L1 immunotherapy efficacy in lung cancer
6个月前
已完结
皖公网安备34019202002308
